Source: https://patents.google.com/patent/US8802130B2/en
Timestamp: 2018-12-16 00:14:45
Document Index: 450591171

Matched Legal Cases: ['Application No. 60', '§120', 'art 1', 'art 2', 'art 3', 'Application No. 04815715', 'Application No. 04815715', 'Application No. 20', 'art 5', '§505']

US8802130B2 - Sublingual buccal effervescent - Google Patents
Sublingual buccal effervescent Download PDF
US8802130B2
US8802130B2 US11511098 US51109806A US8802130B2 US 8802130 B2 US8802130 B2 US 8802130B2 US 11511098 US11511098 US 11511098 US 51109806 A US51109806 A US 51109806A US 8802130 B2 US8802130 B2 US 8802130B2
US11511098
US20060292219A1 (en )
S. Indiran Pather
Rajendra K. Khankari
Jonathan D. Eichman
John Hontz
A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
The present application is a continuation application of U.S. patent application Ser. No. 10/977,029 filed Oct. 29, 2004, which is a continuation of U.S. patent application Ser. No. 10/269,669 filed Oct. 11, 2002, which is a divisional application of U.S. patent application Ser. No. 09/661,693, filed Sep. 14, 2000, which is a continuation application of U.S. patent application Ser. No. 09/327,814 filed Jun. 8, 1999, which is a continuation application of U.S. patent application Ser. No. 09/277,424, filed Mar. 26, 1999, which claims the benefit of U.S. Provisional Application No. 60/079,652 filed on Mar. 27, 1998, the benefit of which is claimed under 35 U.S.C. §120 and the disclosure of which is incorporated by reference herein.
The present invention relates to pharmaceutical compositions, and more particularly to pharmaceutical compositions for oral administration of a medicament, which contain an effervescent agent for enhancing oral drug absorption across the buccal, sublingual, and gingival mucosa.
Effervescents have been shown to be useful and advantageous for oral administration. See Pharmaceutical Dosage Forms: Tablets Volume I, Second Edition. A. Lieberman. ed. 1989, Marcel Dekker, Inc. As discussed in this text, and as commonly employed, an effervescent tablet is dissolved in water to provide a carbonated or sparkling liquid drink. See also U.S. Pat. Nos. 5,102,665 and 5,468,504 to Schaeffer, herein incorporated by reference. In such a drink, the effervescent helps to mask the taste of medicaments.
Effervescent compositions have also been employed for use as taste masking agents in dosage forms which are not dissolved in water prior to administration. For example, U.S. Pat. No. 4,639,368 describes a chewing gum containing a medicament capable of absorption through the buccal cavity and containing a taste masking amount of an effervescent.
More recently effervescents have been employed to obtain rapid dissolution and/or dispersion of the medicament in the oral cavity. See U.S. Pat. Nos. 5,178,878 and 5,223,264. The effervescent tends to stimulate saliva production thereby providing additional water to aid in further effervescent to a faster onset of action and/or improved bioavailability action. These dosage forms give an agreeable presentation of the drug, particularly for patients who have difficulty in swallowing tablets or capsules. PCT application WO 97/06786 describes pre-gastric absorption of certain drugs using rapidly-disbursing dosage forms.
Various proposals have been advanced for oral mucosal administration of various drugs. When drugs are absorbed from the oral mucosa, they bypass the gastrointestinal and hepatic metabolism process. This can lead of a drug. However, many compounds do not rapidly penetrate the oral mucosa. See, e.g., Christina Graffner, Clinical Experience with Novel Buccal and Sublingual Administration; NOVEL DRUG DELIVERY AND ITS THERAPEUTIC APPLICATION, edited by L. F. Prescott and W. S. Nimmo (1989); David Harris & Joseph R. Robinson, Drug Delivery via the Mucous Membranes of the Oral Cavity; JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 81 (January 1992); Oral Mucosal Delivery, edited by M. J. Rathbone, which are herein incorporated by reference. The compounds which may be well absorbed per-orally (through the gastrointestinal tract) may not be well absorbed through the mucosa of the mouth because the oral mucosa is less permeable than the intestinal mucosa and it does not offer as big a surface area as the small intestine.
Despite these and other efforts toward increasing the permeation of medicaments across the oral mucosa, there have been unmet needs for improved methods of administrating medicaments across the oral mucosa.
The pharmaceutical compositions of the present invention comprise an orally administrable medicament in combination with an effervescent agent used as penetration enhancer to influence the permeability of the medicament across the buccal, sublingual, and gingival mucosa.
One aspect of this invention is to use effervescent as penetration enhancers for influencing oral drug absorption. Effervescent agents can be used alone or in combination with other penetration enhancers, which leads to an increase in the rate and extent of absorption of an active drug. It is believed that such increase can rise from one or all of the following mechanisms:
1. reducing the mucosal layer thickness and/or viscosity;
2. tight junction alteration;
3. inducing a change in the cell membrane structure; and
4. increasing the hydrophobic environment within the cellular membrane.
The present dosage forms should include an amount of an effervescent agent effective to aid in penetration of the drug across the oral mucosa. Preferably, the effervescent is provided in an amount of between about 5% and about 95% by weight, based on the weight of the finished tablet, and more preferably in an amount of between about 30% and about 80% by weight. It is particularly preferred that sufficient effervescent material be provided such that the evolved gas is more than about 5 cm3 but less than about 30 cm3, upon exposure of the tablet to an aqueous environment. However, the amount of effervescent agent must be optimized for each specific drug.
The term “effervescent agent” includes compounds which evolve gas. The preferred effervescent agents evolve gas by means of a chemical reaction which takes place upon exposure of the effervescent agent (an effervescent couple) to water and/or to saliva in the mouth. This reaction is most often the result of the reaction of a soluble acid source and a source of carbon dioxide such as an alkaline carbonate or bicarbonate. The reaction of these two general compounds produces carbon dioxide gas upon contact with water or saliva. Such water-activated materials must be kept in a generally anhydrous state and with little or no absorbed moisture or in a stable hydrated form, since exposure to water will prematurely disintegrate the tablet. The acid sources may be any which are safe for human consumption and may generally include food acids, acid and hydrite antacids such as, for example: citric, tartaric, amalic, fumeric, adipic, and succinics. Carbonate sources include dry solid carbonate and bicarbonate salt such as, preferably, sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium carbonate and the like. Reactants which evolve oxygen or other gasses and which are safe for human consumption are also included.
The effervescent agent(s) of the present invention is not always based upon a reaction which forms carbon dioxide. Reactants which evolve oxygen or other gasses which are safe for human consumption are also considered within the scope. Where the effervescent agent includes two mutually reactive components, such as an acid source and a carbonate source, it is preferred that both components react completely. Therefore, an equivalent ratio of components which provides for equal equivalents is preferred. For example, if the acid used is diprotic, then either twice the amount of a mono-reactive carbonate base, or an equal amount of a di-reactive base should be used for complete neutralization to be realized. However, in other embodiments of the present invention, the amount of either acid or carbonate source may exceed the amount of the other component. This may be useful to enhance taste and/or performance of a tablet containing an overage of either component. In this case, it is acceptable that the additional amount of either component may remain unreacted.
The present dosage forms may also include in amounts additional to that required for effervescence a pH adjusting substance. For drugs that are weakly acidic or weakly basic, the pH of the aqueous environment can influence the relative concentrations of the ionized and unionized forms of the drug present in solution according to the Henderson-Hasselbach equation. The pH solutions in which an effervescent couple has dissolved is slightly acidic due to the evolution of carbon dioxide. The pH of the local environment, e.g., saliva in immediate contact with the tablet and any drug that may have dissolved from it, may be adjusted by incorporating in the tablet a pH adjusting substances which permit the relative portions of the ionized and unionized forms of the drug to be controlled. In this way, the present dosage forms can be optimized for each specific drug. If the unionized drug is known or suspected to be absorbed through the cell membrane (transcellular absorption) it would be preferable to alter the pH of the local environment (within the limits tolerable to the subject) to a level that favors the unionized form of the drug. Conversely, if the ionized form is more readily dissolved the local environment should favor ionization.
The active ingredient suitable for use in the present dosage forms can include systematically distributable pharmaceutical ingredients, vitamins, minerals, dietary supplements, as well as non-systematically distributable drugs. Preferably, the active ingredient is a systemically active pharmaceutical ingredient which is absorbable by the body through the oral mucosa. Although the dosage forms can be employed with a wide range of drugs, as discussed below, it is especially suitable for drugs and other pharmaceutical ingredients which suffer significant loss of activity in the lumen of the gastrointestinal tract or in the tissues of the gastrointestinal tract during absorption process or upon passage through the liver after absorption in the intestinal tract. Absorption through the oral mucosa allows the drug to enter the systemic circulation without first passing through the liver, and thus alleviates the loss of activity upon passage through the liver.
Pharmaceutical ingredients may include, without limitation, analgesics, anti-inflammatories, antipyretics, antibiotics, antimicrobials, laxatives, anorexics, antihistamines, antiasthmatics, antidiuretics, antiflatulents, antimigraine agents, antispasmodics, sedatives, antihyperactives, antihypertensives, tranquilizers, decongestants, beta blockers; peptides, proteins, oligonucleotides and other substances of biological origin, and combinations thereof. Also encompassed by the terms “active ingredient(s)”, “pharmaceutical ingredient(s)” and “active agents” are the drugs and pharmaceutically active ingredients described in Mantelle, U.S. Pat. No. 5,234,957, in columns 18 through 21. That text of Mantelle is hereby incorporated by reference. Alternatively or additionally, the active ingredient can include drugs and other pharmaceutical ingredients, vitamins, minerals and dietary supplements as the same are defined in U.S. Pat. No. 5,178,878, the disclosure of which is also incorporated by reference herein.
The dosage form preferably includes an effervescent couple, in combination with the other ingredients to enhance the absorption of the pharmaceutical ingredient across the oral mucosa and to improve the disintegration profile and the organoleptic properties of the dosage form. For example, the area of contact between the dosage form and the oral mucosa, and the residence time of the dosage form in the oral cavity can be improved by including a bioadhesive polymer in this drug delivery system. See, e.g., Mechanistic Studies on Effervescent-Induced Permeability Enhancement by Jonathan Eichman (1997), which is incorporated by reference herein. Effervescence, due to its mucus stripping properties, would also enhance the residence time of the bioadhesive, thereby increasing the residence time for the drug absorption. Non-limiting examples of bioadhesives used in the present invention include, for example, Carbopol 934 P, Na CMC, Methocel, Polycarbophil (Noveon AA-1), HPMC, Na alginate, Na Hyaluronate and other natural or synthetic bioadhesives.
In addition to the effervescence-producing agents, a dosage form according to the present invention may also include suitable non-effervescent disintegration agents. Non-limiting examples of non-effervescent disintegration agents include: microcrystalline, cellulose, croscarmellose sodium, crospovidone, starches, corn starch, potato starch and modified starches thereof, sweeteners, clays, such as bentonite, alginates, gums such as agar, guar, locust bean, karaya, pecitin and tragacanth. Disintegrants may comprise up to about 20 weight percent and preferably between about 2 and about 10% of the total weight of the composition.
In addition to the particles in accordance with the present invention, the dosage forms may also include glidants, lubricants, binders, sweeteners, flavoring and coloring components. Any conventional sweetener or flavoring component may be used. Combinations of sweeteners, flavoring components, or sweeteners and flavoring components may likewise be used.
Coloring agents may include titanium dioxide, and dyes suitable for food such as those known as F.D.&C. dyes and natural coloring agents such as grape skin extract, beet red powder, beta-carotene, annato, carmine, turmeric, paprika, etc. The amount of coloring used may range from about 0.1 to about 3.5 weight percent of the total composition.
Flavors incorporated in the composition may be chosen from synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plants, leaves, flowers, fruits and so forth and combinations thereof. These may include cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leave oil, oil of nutmeg, oil of sage, oil of bitter almonds and cassia oil. Also useful as flavors are vanilla, citrus oil, including lemon, orange, grape, lime and grapefruit, and fruit essences, including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth. Flavors which have been found to be particularly useful include commercially available orange, grape, cherry and bubble gum flavors and mixtures thereof. The amount of flavoring may depend on a number of factors, including the organoleptic effect desired. Flavors may be present in an amount ranging from about 0.05 to about 3 percent by weight based upon the weight of the composition. Particularly preferred flavors are the grape and cherry flavors and citrus flavors such as orange.
One aspect of the invention provides a solid, oral tablet dosage form suitable for sublingual, buccal, and gingival administration. Excipient fillers can be used to facilitate tableting. The filler desirably will also assist in the rapid dissolution of the dosage form in the mouth. Non-limiting examples of suitable fillers include: mannitol, dextrose, lactose, sucrose, and calcium carbonate.
Tablets can either be manufactured by direct compression, wet granulation or any other tablet manufacturing technique. See, e.g., U.S. Pat. Nos. 5,178,878 and 5,223,264, which are incorporated by reference herein. The tablet may be a layered tablet consisting of a layer of the active ingredient sandwiched between a bioadhesive layer and an effervescence layer. Other layered forms which include the ingredients set forth above in layers of diverse compositions.
Effervescence Level: Between 5%-95%
Tablet size: Between 3/16″-⅝″
Tablet hardness: Between 5N and 80N
Route of Administration: Sublingual, Buccal, Gingival
The dosage form may be administered to a human or other mammalian subject by placing the dosage form in the subject's mouth and holding it in the mouth, either adjacent a cheek (for buccal administration), beneath the tongue (for sublingual administration) and between the upper lip and gum (for gingival administration). The dosage form spontaneously begins to disintegrate due to the moisture in the mouth. The disintegration, and particularly the effervescence, stimulates additional salivation which further enhances disintegration.
The dosage form should include Fentanyl, an effervescent and pH adjusting substance so that the pH is adjusted to neutral (or slightly higher) since the pKa of fentanyl is 7.3. At this pH, the aqueous solubility of this poorly water-soluble drug would not be compromised unduly, and would permit a sufficient concentration of the drug to be present in the unionized form.
Two fentanyl formulations, each containing 36% effervescence, were produced. These tablets were compressed using half-inch shallow concave punches.
FORMULATION COMPONENT QUANTITY (MG)
SHORT Fentanyl, citrate, USP 1.57
DISINTEGRATION Lactose monohydrate 119.47
TIME Microcrystalline 119.47
Cellulose, Silicified
Sodium carbonate, 46.99
Sodium bicarbonate 105
Citric acid, anhydrous 75
Polyvinylphrrolidone, 25
Colloidal silicon dioxide 2.5
Total tablet mass 500
LONG Fentanyl citrate, USP 1.57
DISINTEGRATION Lactose monohydrate 270.93
TIME Sodium carbonate, 40.00
The dosage form included prochlorperazine (pKa=8.1), an effervescent and pH adjusting substance so that a slightly higher pH is produced to facilitate the permeation enhancement.
With respect to prochlorperazine, an anti-emetic drug, two formulations, buccal and sublingual, were developed. The buccal tablets were compressed as quarter inch diameter biconvex tablets, whereas the sublingual tablets were three-eighths inch diameter biconvex tablets. These dimensions were chosen to give a comfortable fit in the respective part of the oral cavity for which they were designed. The formulae for these tablets are as follows:
FORMULATION COMPONENT NAME QUANTITY (MG)
BUCCAL Prochlorperazine 5.00
Sodium Bicarbonate 15.52
Citric Acid, Anhydrous 11.08
Sodium Bicarbonate 45.78
HPMC K4M Prem 5.00
Dicalcium phosphate 5.00
Mannitol 11.67
Magnesium Stearate 0.95
SUBLINGUAL Prochlorperazine 5.00
Sodium Bicarbonate 61.25
Citric Acid, Anhydrous 43.75
Sodium Bicarbonate 95
Sodium carbonate 91.25
HPMC Methocel K4M Prem 40
Mannitol 60
Magnesium Stearate 3.75
1. A method of manufacturing a compressed tablet suitable for direct oral administration across the oral mucosa, said method comprising the steps of:
a) providing an amount of a salt of fentanyl that is pharmaceutically effective for systemic distribution and for oral mucosal administration;
b) providing at least one saliva activated effervescent couple in an amount that is effective for both tablet disintegration and an increase in either the rate or extent of absorption of said orally administrable medicament across the oral mucosa, wherein said amount of said at least one effervescent couple ranges from about 5% by weight to about 95% by weight;
c) producing a mixture from said pharmaceutically effective amount of a composition consisting of a salt of fentanyl and said saliva activated effervescent couple; and
d) compressing at least a portion of said mixture so as to form at least one tablet.
2. The method of claim 1, further comprising the step of selecting a bioadhesive and producing said mixture including same.
3. The method of claim 1, further comprising the step of: selecting a non-effervescent disintegration agent and producing said mixture including same.
4. The method of claim 1, further comprising the step of: selecting one or more glidants, lubricants, binders, sweeteners, flavoring and coloring components and producing said mixture including same.
5. The method of claim 1, wherein said at least one saliva activated effervescent couple is present in an amount between about 20% by weight and 80% by weight.
6. The method according to claim 1, wherein said at least one effervescent couple is present in an amount between about 5% by weight to about 80% by weight.
7. The method according to claim 1, wherein said at least one effervescent couple is present in an amount sufficient to evolve a gas in an amount between about 5 cm3 to about 30 cm3.
8. The method according to claim 1, wherein said mixture further comprises a pH adjusting substance.
9. The method according to claim 8, wherein said pH adjusting substance is a base and said base is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate.
10. The method according to claim 1 further comprising the step of selecting a pH adjusting substance and determining what amount of same is sufficient to change the pH of a local environment of said tablet at a site of absorption in the mouth and producing said mixture including same.
11. The method according to claim 10, wherein said pH adjusting substance is a base.
12. The method according to claim 11, wherein said base is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate.
13. A method of manufacturing a tablet suitable for direct oral administration across the oral mucosa, said method comprising the steps of:
a) selecting at least one orally administrable medicament consisting of a salt of fentanyl, capable of existing in an ionized form and a unionized form in aqueous environment;
b) providing a pharmaceutically effective amount for systemic distribution and for oral mucosal administration of said at least one orally administrable medicament;
c) selecting at least one saliva activated effervescent couple;
d) selecting a basic pH adjusting substance in an amount sufficient to change the pH of a local environment of said tablet at a site of absorption in the mouth to favor said unionized form of said medicament;
e) producing a mixture from said medicament, said selected saliva activated effervescent couple and said pH adjusting substance, in said predetermined amounts; and
f) compressing at least a portion of said mixture so as to form at least one tablet.
14. The method according to claim 13, wherein said basic pH adjusting substance is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate.
15. The method of claim 13 further comprising the step of selecting a bioadhesive and producing said mixture including same.
16. The method of claim 13 wherein said amount of said at least one effervescent couple ranges from about 5% by weight to about 80% by weight.
17. The method of claim 13, further comprising the step of: selecting one or more glidants, lubricants, binders, sweeteners, flavoring and coloring components and producing said mixture including same.
18. A method of manufacturing a tablet suitable for direct oral administration across the oral mucosa, said method comprising the steps of:
c) selecting at least one saliva activated effervescent couple in an amount of from about 5% by weight to about 80% by weight;
d) selecting a basic pH adjusting substance from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium dihydrogen phosphate, in an amount sufficient to change the pH of a local environment of said tablet at a site of absorption in the mouth to favor said unionized form of said medicament;
e) selecting a bioadhesive substance suitable for use in the oral cavity;
f) selecting one or more excipient from the group consisting of glidants, lubricants, binders, sweeteners, flavoring and coloring components;
g) producing a mixture from said medicament, said selected saliva activated effervescent couple, said pH adjusting substance, said bioadhesive; and said excipient; and
h) compressing at least a portion of said mixture so as to form at least one tablet.
19. The tablet produced by the method of claim 1.
20. The tablet produced by the method of claim 14.
21. The tablet produced by the method of claim 15.
22. The tablet produced by the method of claim 13.
23. The tablet produced by the method of claim 18.
24. The method of claim 1, wherein the salt of fentanyl comprises fentanyl citrate.
25. The method of claim 13, wherein the salt of fentanyl comprises fentanyl citrate.
26. The method of claim 18, wherein the salt of fentanyl comprises fentanyl citrate.
US11511098 1998-03-27 2006-08-28 Sublingual buccal effervescent Active 2022-08-05 US8802130B2 (en)
US7965298 true 1998-03-27 1998-03-27
US27742499 true 1999-03-26 1999-03-26
US09327814 US6200604B1 (en) 1998-03-27 1999-06-08 Sublingual buccal effervescent
US66169300 true 2000-09-14 2000-09-14
US10269669 US20030091629A1 (en) 1998-03-27 2002-10-11 Sublingual buccal effervescent
US10977029 US20050064030A1 (en) 1998-03-27 2004-10-29 Sublingual buccal effervescent
US11511098 US8802130B2 (en) 1998-03-27 2006-08-28 Sublingual buccal effervescent
US10977029 Continuation US20050064030A1 (en) 1998-03-27 2004-10-29 Sublingual buccal effervescent
US20060292219A1 true US20060292219A1 (en) 2006-12-28
US8802130B2 true US8802130B2 (en) 2014-08-12
ID=46281346
US10269669 Abandoned US20030091629A1 (en) 1998-03-27 2002-10-11 Sublingual buccal effervescent
US10977029 Abandoned US20050064030A1 (en) 1998-03-27 2004-10-29 Sublingual buccal effervescent
US11511098 Active 2022-08-05 US8802130B2 (en) 1998-03-27 2006-08-28 Sublingual buccal effervescent
US (3) US20030091629A1 (en)
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
DE10207394B4 (en) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag A taste masked wafer-shaped pharmaceutical preparation
DE602004031771D1 (en) * 2003-12-31 2011-04-21 Cima Labs Inc Effervescent forms of opiates for oral administration and methods for administering oxycodone
WO2005065317A3 (en) * 2003-12-31 2006-01-19 Vikas Agarwal Effervescent oral fentanyl dosage form
JP5179757B2 (en) * 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド Compositions and methods of use thereof for delivering a hypnotic agent via the oral mucosa
CA2609330A1 (en) * 2005-05-25 2006-11-30 Transcept Pharmaceuticals, Inc. Solid compositions and methods for treating middle-of-the night insomnia
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
CA2670886A1 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US1262888A (en) 1917-02-20 1918-04-16 Albert Westlake Mouth-tablet.
US1263888A (en) 1918-01-10 1918-04-23 J T Vail Wave-motor.
US2887437A (en) 1956-08-22 1959-05-19 Pfizer & Co C Palatable vitamin tablet containing an amino acid
US3042531A (en) 1959-12-09 1962-07-03 Leslie Salt Company Method of making a compressed tablet
US3131123A (en) 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
GB1212704A (en) 1967-11-21 1970-11-18 Prodotti Antibiotici Spa Vaginal suppositories
US3577490A (en) 1967-10-02 1971-05-04 Miles Lab Effervescent tablet and process for making same
NL7302521A (en) 1973-02-23 1974-08-27 Foaming, effervescent capsules - contg. therapeutic agents for rectal and vaginal use
US3888976A (en) 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US3961041A (en) 1974-11-14 1976-06-01 Interx Research Corporation Effervescent enteric coated L-dopa formulation and method of using the same
US3962417A (en) 1974-03-27 1976-06-08 Howell Charles J Dentifrice
US4147768A (en) 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
US4187286A (en) 1979-01-02 1980-02-05 G&W Laboratories, Inc. Contraceptive suppository
US4289751A (en) 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
US4493848A (en) 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4503031A (en) 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4613497A (en) 1984-02-29 1986-09-23 Health Products Development, Inc. Dry, water-foamable pharmaceutical compositions
US4687662A (en) 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US4689218A (en) 1985-11-12 1987-08-25 Zambon S.P.A. Effervescent composition with analgesic activity
US4717723A (en) 1984-10-16 1988-01-05 Reckitt & Colman Products Limited Pharmaceutical compositions
US4725427A (en) 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US4753792A (en) 1984-08-21 1988-06-28 Aberg T Tooth cleaning tablet
EP0275834A1 (en) 1986-12-29 1988-07-27 Warner-Lambert Company Continuous process for producing a comestible tablet
US4853211A (en) 1982-03-05 1989-08-01 Eisai Co., Ltd. Stable, effervescent vaginal suppositories
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US4876039A (en) 1986-11-04 1989-10-24 Dow Corning Corporation Process for preparing silicone microparticles cured by a Michael addition reaction
EP0361680A2 (en) 1988-08-26 1990-04-04 Rhone Poulenc Rorer Limited Morphine-containing composition
US4940588A (en) 1984-10-30 1990-07-10 Elan Corporation Controlled release powder and process for its preparation
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
US5028411A (en) 1984-04-19 1991-07-02 National Research Development Corporation Pharmaceutical compositions
US5053396A (en) 1985-08-27 1991-10-01 Blass David H Therapeutic composition
US5055306A (en) 1987-10-22 1991-10-08 Aps Research Limited Sustained-release formulations
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5102665A (en) 1988-06-24 1992-04-07 Glaxo Group Limited Pharmaceutical compositions
DE4139883A1 (en) 1991-11-29 1993-06-03 Michael Prof Dr Dittgen Prodn. of bio-adhesive medicament, e.g. oral or vaginal tablet - comprises mixing drug with swellable, bio-adhesive polymer, dispersant and opt. binder
EP0396335B1 (en) 1989-04-28 1994-02-02 Beecham Group p.l.c. Pharmaceutical formulation
US5314904A (en) 1991-12-17 1994-05-24 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
EP0354973B1 (en) 1985-09-11 1995-03-15 K.V. Pharmaceuticals, Inc. Drug delivery system
US5401513A (en) * 1989-09-15 1995-03-28 Cima Labs, Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5445827A (en) 1988-11-12 1995-08-29 Bayer Aktiengesellschaft Effervescent ibuprofen preparations
US5464632A (en) 1991-07-22 1995-11-07 Laboratoires Prographarm Rapidly disintegratable multiparticular tablet
US5468504A (en) 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
US5501861A (en) 1992-01-29 1996-03-26 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
CA2211586A1 (en) 1995-01-30 1996-08-08 Societe Civile Mission Effervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection___________________________________________
US5559096A (en) 1991-04-15 1996-09-24 Applied Microbiology, Inc. Pharmaceutical compositions against gastric disorders
EP0737473A1 (en) 1989-10-02 1996-10-16 Cima Labs, Inc. Effervescent dosage form
US5624687A (en) 1991-04-15 1997-04-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-dissolution solid preparation
FR2732217B1 (en) 1995-03-29 1997-06-06 Hesnard Xavier Form solid oral administration has
GB2307857A (en) 1995-12-04 1997-06-11 Euro Celtique Sa An effervescent tablet containing tramadol
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5656284A (en) 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
US5807688A (en) 1995-05-27 1998-09-15 Zeneca Limited Catalytic antibodies for carbamate activation by a non-spontaneous reaction mechanism
US5853748A (en) 1994-08-31 1998-12-29 Cortecs (Uk) Limited Pharmaceutical compositions
EP0839526A3 (en) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US6034085A (en) 1994-11-02 2000-03-07 Bristol-Myers Squibb Co. Salt form of nefazodone for use in extended release formulations
US6068853A (en) 1994-04-13 2000-05-30 Novartis Corporation Temporally controlled drug delivery systems
US6071539A (en) 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6106861A (en) 1997-07-21 2000-08-22 Laboratoires Prographarm Multiparticulate tablet disintegrating in less than 40 seconds in the mouth
US6117912A (en) 1995-11-06 2000-09-12 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline for treating certain selegiline-responsive diseases and conditions
US6129906A (en) 1995-11-11 2000-10-10 The Procter & Gamble Company Silicone containing powders
US6171617B1 (en) 1996-02-20 2001-01-09 Losan Pharma Gmbh Effervescent ibuprofen preparation and process for the production thereof
US6190697B1 (en) 1997-10-27 2001-02-20 Gerhard Gergely Effervescent formulation containing plant extract
US6242002B1 (en) 1998-03-31 2001-06-05 Arzneimittelwerk Dresden Gmbh Effervescent formulations
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6316027B1 (en) 1995-08-18 2001-11-13 R. P. Scherer Technologies, Inc. Fast-dissolving dosage forms for dopamine agonists
US20010041165A1 (en) 1996-05-17 2001-11-15 Merck & Co., Inc. Effervescent bisphosphonate formulation
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US20020110578A1 (en) 1998-03-27 2002-08-15 Pather Sathasivan Indiran Sublingual buccal effervescent
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6759059B1 (en) 1998-09-24 2004-07-06 Diabact Ab Fentanyl composition for the treatment of acute pain
US6761910B1 (en) 1998-09-24 2004-07-13 Diabact Ab Pharmaceutical composition for the treatment of acute disorders
WO2004067004A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
US20050037072A1 (en) 1998-03-27 2005-02-17 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US20050142198A1 (en) 2003-12-31 2005-06-30 Cima Labs Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
US20050142197A1 (en) 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US20050163838A1 (en) 2003-12-31 2005-07-28 Cima Labs Inc. Effervescent oral opiate dosage forms and methods of administering opiates
TW200611697A
TW200611686A
CA2218370C (en) 1995-07-31 2006-10-03 Gerhard Gergely Chewable tablet with effervescent action
US20060292219A1 (en) 1998-03-27 2006-12-28 Cima Labs Inc. Sublingual buccal effervescent
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US20080131508A1 (en) 2006-12-01 2008-06-05 Cephalon, Inc Oral transmucosal nicotine dosage form
US20090214442A1 (en) 2006-12-01 2009-08-27 Cephalon, Inc. Oral Transmucosal Nicotine Dosage Form
DE19618543C2 (en) * 1996-05-08 1998-07-02 Ivoclar Ag Curing Light
EP0197504B1 (en) 1985-04-05 1992-10-07 Merck &amp; Co., Inc. Ph-mediated drug delivery system
US5387420A (en) 1988-08-26 1995-02-07 May & Baker Ltd. Morphine-containing efferverscent composition
US5720974A (en) 1992-01-29 1998-02-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
EP1062952B1 (en) 1998-03-11 2003-08-06 Grelan Pharmaceutical Co., Ltd. Bubbling enteric preparations
EP1067905B1 (en) 1998-03-31 2002-09-25 VIATRIS GmbH &amp; Co. KG Fizzy formulations
CA2326502C (en) 1998-03-31 2008-08-05 Asta Medica Aktiengesellschaft Effervescent formulations
US6451339B2 (en) 1999-02-26 2002-09-17 Lipocine, Inc. Compositions and methods for improved delivery of hydrophobic agents
US20050169989A1 (en) 2003-12-31 2005-08-04 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
Non-Patent Citations (328)
2011 Ceph et al., v. Sandoz Proposed Order.
Alternative Routes of Drug Administration-Advantages and Disadvantages (Subject Review), American Academy of Pediatrics Committee on Drugs, Pediatrics, vol. 100, No. 1 Jul. 1997, 143, 147.
Alternative Routes of Drug Administration—Advantages and Disadvantages (Subject Review), American Academy of Pediatrics Committee on Drugs, Pediatrics, vol. 100, No. 1 Jul. 1997, 143, 147.
Altomare, E. et al., "Bioavailability of a New Effervescent Tablet of Ibuprofen in Healthy Volunteers", Eur. J. Clin. Pharmacol. vol. 52, pp. 505-506, (1997).
Amighi, K.; Timmermans, J.; Puigdevall, J.; Baltes, E.; Moës, A.. J.; Peroral Sustained-Release Film-Coated Pellets as a Means to Overcome Physicochemical and Biological Drug-Related Problems. I. In Vitro Development and Evaluation, Drug Development and Industrial Pharmacy, 1998, pp. 509-515, vol. 24, No. 6.
Apr. 1, 2009 Redacted Park Declaration in Support of Watson Reply in Support of Motion to Dismiss Amended Complaint, C.A. No. 08-CV-00330-SLR.
Apr. 1, 2009 Redacted Watson et al., Reply Brief in Support of Motion to Dismiss—Amended Complaint, C.A. No. 08-330-SLR.
Apr. 1, 2010 Redacted Cephalon Reply in Support of Motion to Modify Protective Orders.
Apr. 11, 2011 Ceph et al. v. Mylan et al., Order for Scheduling Conference.
Apr. 11, 2011 Ceph et al. v. Sandoz Fifth Stipulated Amendment to Scheduling Order.
Apr. 15, 2008 Watson ltr re: Notification of Certification of Invalidity, Unenforceability and/or Non-Infringement for U.S.
Apr. 15, 2010 Answer to Counterclaims, Civil Action No. 10-330-SLR. Ceph et al. v. Sandoz.
Apr. 15, 2011 Joint Claim Construction Chart by Cephalon et al. and Sandoz Inc.
Apr. 19, 2010 Ceph et al. v. Watson et al., Proposed Joint Pretrial Order.
Apr. 20, 2010 Booker Declaration in Support of Motion Responsive Post-Trial Brief on Validity—Exhibits 1-5.
Apr. 20, 2010 Deposition of Stephen R. Byrne.
Apr. 20, 2010 Order Setting Scheduling Teleconference. Ceph et al. v. Sandoz.
Apr. 21, 2011 Redacted Version of 98 Answering Brief in Opposition, Part 1 of 3 by Sandoz Inc., (Attachments: #1 Part 2 of 3, #2 Part 3 of 3).
Apr. 26, 2010 Redacted Pretrial Order, Civil Action No. 08-330-SLR.
Apr. 26, 2011 Plaintiffs' Amended Notice of Appeal to the United States Court of Appeals for the Federal Circuit, Case: 1:08-cv-00330-SLR, Document 339.
Apr. 27, 2009 Ceph et al. v. Watson et al., Answer and Counterclaims to Amended Complaint.
Apr. 27, 2010 Telephone conversation dated Apr. 19, 2010, Apr. 20, 2010 and Apr. 21, 2010 re: 04815716.8 for auxiliary.
Apr. 29, 2009 Ceph et al. v. Watson et al., Defendant's Second Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories.
Apr. 29, 2009 Ceph et al. v. Watson et al., Response to Defendants' Invalidity Contentions, Civil Action No. 08-330-SLR.
Apr. 3, 2009 Order Denying 95 Motion to Dismiss, denying 15 Motion to Dismiss for Lack of Jurisdiction Over the Person Motion to Dismiss for Failure to State a Claim, denying 12 Motion to Dismiss for Failure to State a Claim. Signed by Judge Sue L. Robinson, C.A. No. 08-330-SLR, Ceph et al. v. Watson et al.
Apr. 5, 2011 Redacted Version of 89 Opening Brief in Support, of Plaintiffs' Motion to Stay Proceedings by Cephalon et al., (Attachments: # 1 Exhibit A-B). Search Query of Fentanyl.
Apr. 5, 2011 Redacted Version of 92 Letter, to Judge Thynge from Poff regarding Defendant's Response to Plaintiff's Mar. 28, 2011 Letter by Sandoz Inc.
Apr. 5, 2011 Redacted Version of 96 Letter, to Judge Thynge from Poff regarding Sandoz opposing an extension of pretrial dates requested by Ceph. (ltr dated Mar. 29, 2011).
Apr. 8, 2009 Redacted Version of 125 Reply Brief by Watson Pharma Inc., Watson Pharmaceuticals Inc., Watson Laboratories Inc. (Attachments: #1, Ex. 1-12) (Fineman, Steven).
Apr. 8, 2009 Redacted Version of 126 Declaration by Watson Pharma Inc., Watson Pharmaceuticals Inc., Watson Laboratories Inc. (Fineman, Steven).
Apr. 9, 2010 Redacted Plaintiff's Brief in Opposition to Defendants Motion to Exclude Certain CO2 Testing, C.A. No. 08-330-SLR.
Apr. 9, 2010 Redacted Watson Motion to Exclude CO2 Testing.
Audus, K., et al, "The Use of Cultured Epithelial and Endothelial Cells for Drug Transport and Metabolism Studies", Pharmaceutical Research, vol. 7, No. 5, 1990, p. 435.
Audus, K.L., "Buccal Epithelial Cell Cultures as a Model to Study Oral Mucosal Drug Transport and Metabolism" Oral Mucosal Drug Delivery, Ch. 6, pp. 101-115 (1996).
Aug. 10, 2010 Redacted Plaintiffs Opposition to Motion to Strike.
Aug. 11, 2010 Redacted Declaration of Bryan Braunel re Motion to Strike Exp Testimony.
Aug. 13, 2010 Booker Declaration in Support of Ceph et al., Post Trial Reply Brief on Infringement.
Aug. 13, 2010 Order Rescheduling ADR Teleconference, C.A. No. 10-123-SLR/MPT.
Aug. 13, 2010 Redacted Booker Declaration in Support of Reply Post Trial Brief with Ex. 1 and 2.
Aug. 13, 2010 Redacted Plaintiffs Reply Post-Trial Brief—Corrected.
Aug. 13, 2010 Redacted Post-trial Brief of Watson—Document 273—filed Aug. 20, 2010.
Aug. 16, 2010 Ceph et al., v. Watson et al., Plaintiffs' Brief in Opposition to Defendants' Motion to Strike Expert Testimony.
Aug. 16, 2010 Redacted Booker Declaration in Support of Opposition to Motion to Strike with Ex. A & B.
Aug. 30, 2010 2nd Stipulated Amendment to Scheduling Order re: Doc Production, Civil Action No. 10-123-SLR. Ceph et al. v. Sandoz.
Aug. 30, 2010 Cephalon Notice of Service re: 1st Set Interrogatories and Request for Production of Documents to Sandoz.
Aug. 31, 2010 Order Scheduling ADR Teleconference—Sep. 22, 2010, CA 10-123-SLR/MPT.
Aug. 31, 2010 Sandoz Notice of Service re 1st Set interrogatories and Request for Production of Documents to Sandoz.
Aug. 5, 2010 Order Regarding Discovery Matter, C.A. No. 10-123-SLR/MPT. Ceph et al. v. Sandoz.
Aug. 5, 2010 Order Scheduling ADR Teleconference, C.A. No. 10-123-SLR/MPT.
Aungst, B.J., "Oral Mucosal Permeation Enhancement: Possibilities and Limitations" Oral Mucosal Drug Delivery, Ch. 4, pp. 65-81 (1996).
Berko, S.; Regdon Jun, G.; Erös, I.; Influence of pH Change on Drug Release from Rectal Suppositories, Die Pharmazie, Apr. 2000, p. 324, vol. 55., Govi-Verlag Pharmazeutischer Verlag GmbH, Eschbom.
Cephalon Inc., and Cima Labs, Inc., v. Barr Pharmaceuticals Inc., and Barr Laboratories Inc., Case No. 08-cv-00455 (UNA), answer, affirmative defenses and counterclaims.
Cephalon Inc., and Cima Labs, Inc., v. Barr Pharmaceuticals Inc., and Barr Laboratories Inc., complaint for patent infringement.
Cephalon Inc., and Cima Labs, Inc., v. Watson Pharmaceuticals Inc., and Watson Laboratories Inc., complaint for patent infringement, Civil Action # 08-330.
Cephalon v. Watson, Para. IV-Redacted.
Cephalon v. Watson, Para. IV—Redacted.
Chen et al., "Studies on formulations of fentanyl buccal adhesive tablets", Zhonggup Yiyao Gongye Zazhi, 1997, 28 (3), 129-131.
Clinical Pharmacology FDA Submission, Clinical Pharmacology and Biopharmaceutics Reviews, NDA 21-947, Fentanyl Effervescent Buccal Tablet DFS, pp. 1-86, 31 pages withheld.
Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain 2001; 91 (1-2): 123-30.
Coster ltr to the Speaker, Leader and Director re: Protecting Funding for FDA Office of Generic Drugs in Final 2011 Budget, dated Mar. 18, 2011.
Darwish M, Messina J, Tempero K. Relative bioavailability and dose proportionality of a novel effervescent form of fentanyl in healthy volunteers [abstract]. 2005 Annual Meeting, American Society of Anesthesiologists; Oct. 22-26, 2005; Atlanta (GA).
Darwish M, Tempero K, Kirby M, et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 2005; 44 (12): In press.
Darwish, M. et al., "Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate", J. Clin. Pharmacol. vol. 47, pp. 343-350 (2007).
Dec. 1, 2010 Ceph et al. v. Sandoz, Notice of Service of Sandoz's Objections and Responses to Notice of Rule 30(b)(6) Deposition of Sandoz, Civil Action No. 10-123-SLR.
Dec. 10, 2010 Ceph et al. v. Sandoz, Order Setting Continued Mediation Conference, C.A. No. 10-123-SLR/MPT.
Dec. 23, 2008, Ceph et al. v. Barr et al., Barr's First Set of Interrogatories to Ceph et al., (Nos. 1-10), Case No. 08pcv-00455 (JJF).
Dec. 29, 2010 Ceph et al. v. Sandoz, Cephalon Amended Notice of Deposition of Alison Sherwood, Civil Action No. 10-123-SLR.
Dec. 6, 2010 Cephalon and CIMA Notice of Service re Responses and Objections to Sandoz 2nd Notice of Deposition, Civil Action No. 10-123-SLR.
DeGrande et al., "Specialized Oral Mucosal Drug Delivery Systems: Patches" Oral Mucosal Drug Delivery, Ch. 12, pp. 285-313 (1996).
Eichman, J.D., and Robinson, J.R., "Mechanistic Studies on Effervescent-Induced Permeability Enhancement" Pharm. Res. 15(6):925-30 (1998).
Eichman, J.D., Thesis "Mechanistic Studies on Effervescent-Induced Permeability Enhancement" (catalogued at the University of Wisconsin-Madison on Sep. 18, 1998) (on file with the University of Wisconsin-Madison).
Eichman, Jonathan D., "Increased Drug Absorption Through Carbonation: Assessment of Biological Membranes", A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science (Pharmaceutics) at the University of WI-Madison, (1995).
Eichman, Jonathan D., "The Influence of In-Vivo Carbonation on GI Physiological Processes and Drug Permeability", Eur. J. Pharmaceutics and Biopharmaceutics, vol. 44, pp. 33-38, (1997), catalogued Sep. 18, 1998.
EP Communication from EP Patent Office, EP Patent Application No. 04815715.0, dated Mar. 28, 2008.
EP Search Report for EP Patent Application No. EP 00919523 dated Apr. 29, 2002.
EP Search Report for EP Patent Application No. EP 00926341 dated Nov. 23, 2005.
EP Supplemental Search Report for EP Patent Application No. 04815715 dated Nov. 14, 2007.
Feb. 1, 2011 Ceph v. Sandoz, email to Judge Thynge (Fish & Richardson) Marsden re Parties Availability for Mediation.
Feb. 11, 2009 Ceph et al. v. Barr et al., Responses and Objections to Ceph et al. Second Set of Interrogatories (No. 11), Case No. 08-cv-00455 (SLR).
Feb. 11, 2011 Cephalon Notice of Service re: 3rd Supplemental Responses and Objections to Sandoz 1st Interrogatories Nos. 1-13.
Feb. 11, 2011 Order Setting Teleconference re Navinta Discovery Issue, C.A. No. 10-123-SLR/MPT.
Feb. 12, 2010 Joint Claim Construction, Ceph et al. v. Watson et al.
Feb. 14, 2011 Order Setting Mediation Conference Mar. 23, 2011, C.A. No. 10-123-SLR.
Feb. 14, 2011 Sandoz Notice of Service re 3rd Supplemental Responses and Objections to Cephalon 1st Interrogatories, C.A. No. 10-123-SLR.
Feb. 15, 2011 Redacted Ltr to Thynge (Fish and Richardson) Shaw re Cephalon Motion to Compel Navinta-Related Docs.
Feb. 15, 2011 Sealed Letter to the Honorable Mary Pat Thynge from John W. Shaw regarding Plaintiffs' Motion to Compel the Production of Navinta Formulation and Related Documents—re 66, Letter, 67 Letter. (Shaw).
Feb. 16, 2010 Ceph et al., v. Sandoz, Civil Cover.
Feb. 16, 2010 Ceph et al., v. Sandoz, Complaint.
Feb. 16, 2010 Ceph et al., v. Sandoz, Exhibit A—'604 Patent Submitted with Complaint.
Feb. 16, 2010 Ceph et al., v. Sandoz, Exhibit B—'590 Patent Submitted with Complaint.
Feb. 16, 2010 Cephalon Corporate Disclosure Statement Pursuant to Rule 7.1 of the Fed. Rules of CIV. Procedure.
Feb. 16, 2010 CIMA Corporate Disclosure Statement Pursuant to Rule 7.1 of the Fed. Rules of CIV. Procedure.
Feb. 16, 2011 Cephalon Notice of Deposition of Jessica Martori, C.A. No. 10-123-SLR.
Feb. 16, 2011 Redacted 66 Ltr to Thynge (Fish and Richardson) Marsden re: Discovery Dispute, Exhibits A-K.
Feb. 17, 2009 Ceph et al. v. Barr et al., Answer to Counterclaims.
Feb. 17, 2010 Proof of Service, US District Court for the District of Delaware.
Feb. 17, 2010 Report on the Filing or Determination of an Action Regarding a Patent or Trademark, C.A. No. 10-cv-00123-UNA, Ceph et al. v. Sandoz.
Feb. 17, 2010 Sandoz Summons in a Civil Action.
Feb. 17, 2011 Redacted 67 Ltr to Thynge (Fish and Richardson) Shaw re Discovery Dispute, Attachment #1 Exhibits A-C.
Feb. 17, 2011 Redacted 76 Ltr to Thynge (Fish and Richardson) Shaw re Motion to Compel the Production of Navinta Formulation and Related Documents by Sandoz.
Feb. 2, 2011 Ceph v. Sandoz, Order Setting Teleconference re Dates for Continued Mediation.
Feb. 2, 2011 Ceph v. Sandoz, Order Setting Teleconference re: Dates for Discovery Matters.
Feb. 20, 2009 Redacted Watson Defendants Opening Brief in Support of Motion to Dismiss Amended Complaint, C.A. No. 08-330-SLR.
Feb. 20, 2009 Redacted Watson Labs Reply Brief in Support of Motion to Dismiss.
Feb. 20, 2009 Redacted Watson Pharma Reply Brief in Support of Motion to Dismiss, C.A. No. 08-330-SLR.
Feb. 22, 2010 Summons Executed by Cephalon Inc., CIMA LABS Inc. Sandoz Inc. served on Feb. 17, 2010. (Marsden).
Feb. 23, 2009 Ceph et al. v. Barr Pharma et al., Answer, Affirmative Defenses and Counterclaims, Case No. 1:09-cv-00074-SLR.
Feb. 23, 2011 Plaintiffs Notice of Service re Opening Expert Reports, C.A. No. 10-123-SLR.
Feb. 24, 2011 Ceph et al. v. Mylan et al., Complaint w/ Exhibits.
Feb. 24, 2011 Cephalon Disclosure Statement.
Feb. 24, 2011 CIMA Disclosure Statement.
Feb. 24, 2011 Civil Cover Sheet, Ceph et al. v. Mylan et al.
Feb. 24, 2011 Notice of Availability of Magistrate.
Feb. 24, 2011 Report on the Filing or Determination of an Action Regarding a patent or Trademark, C.A. No. 11-CV-164.
Feb. 24, 2011 Supplemental Info. for ANDA Patent Cases.
Feb. 25, 2011 Ceph et al. v. Mylan et al., Affidavit of Service from Shinkowsky served on Smith.
Feb. 25, 2011 Ceph et al. v. Sandoz, Notice of Service Opening Expert Report of Fine, Olsen, and Williams by Cephalon et al.
Feb. 28, 2011 Defendant Notice of Service re: Expert Report of Polli, C.A. No. 10-123-SLR.
Feb. 3, 2011 Redacted Boyer Declaration in Support of Motion to Vacate with Exhibit 1, Ceph et al. v. Watson.
Feb. 3, 2011 Redacted Boyer Declaration in Support of Reply to Motion to Vacate, Ceph et al. v. Watson.
Feb. 3, 2011 Redacted Ceph et al. v. Watson et al. Watson's Reply Brief in Further Support of Its Motion to Vacate the Oct. 28, 2010 Order.
Feb. 4, 2009 Ceph et al. v. Watson et al., Amended Complaint for Patent Infringement, Civil Action No. 08-330 SLR (Redacted).
Feb. 8, 2011 Ceph et al. v. Sandoz, Notice of Deposition of Matthew Bohlman on Feb. 28, 2011.
Feb. 8, 2011 Ceph et al. v. Sandoz, Notice of Deposition of Suni Vandse on Feb. 15, 2011.
Feb. 9, 2011 Redacted Ltr to Thynge (Fish and Richardson) Marsden re: Discovery Dispute.
Feb. 9, 2011 Sealed Letter to Thynge from Shaw regarding Defendant's Objections to Plaintiffs' Motion to Compel re: 66 Letter. (Attachments: #1 Ex. A-C).
Fish & Richardson Ltr to Stronski, Ceph et al. v. Watson re: Alleged Deficiencies in Cephalon's Response to Watson's Interrogatory No. 2, dated May 29, 2009.
Giannos, S.A.; Dinh, S.M.; Berner, B.; Temporally Controlled Drug Delivery Systems: Coupling of pH Oscillators with Membrane Diffusion, Journal of Pharmaceutical Sciences, May 1995, pp. 539-543, vol. 84, No. 5.
Hagerstrom, Helene, "Polymer Gels as Pharmaceutical Dosage Forms: Rheological Performance and Physicochemical Interactions at the Gel-Mucus Interface for Formulations Intended for Mucosal Drug Delivery", Theses from Uppsala University: 3538-Polymer Gels as Pharmaceutical Dosage Forms, pp. 1-3, http://publications. uu. se/theses/abstract.xsql ?dbid=3538&lang=en, 2004.
Hagerstrom, Helene, "Polymer Gels as Pharmaceutical Dosage Forms: Rheological Performance and Physicochemical Interactions at the Gel-Mucus Interface for Formulations Intended for Mucosal Drug Delivery", Theses from Uppsala University: 3538—Polymer Gels as Pharmaceutical Dosage Forms, pp. 1-3, http://publications. uu. se/theses/abstract.xsql ?dbid=3538&lang=en, 2004.
Harris, D. et al., "Drug Delivery via the Mucous Membranes of the Oral Cavity", Journal of Pharmaceutical Sciences, vol. 81(1), pp. 1-10 (1992).
Helene Hagerstrom, "Polymer Gels as Pharmaceutical Dosage Forms" Thesis (Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 293) 2003.
Hessel, P.G., et al., "A Comparison of the availability of prochlorperazine following i.m. buccal and oral administration", International Journal of Pharmaceutics, Jun. 1, 1989, vol. 52, Issue 2, p. 159-164.
http://chemical1and21.com/industrialchem/inorganic/SODIUM%20SULPHATE.htm, Sodium Sulphate, 2 pages.
Impax Lab, Paragraph IV Certification Notice, dated Oct. 6, 2011.
International Search Report for PCT Application No. PCT/US00/07567, dated Jul. 5, 2000.
International Search Report for PCT Application No. PCT/US04/43703, dated Nov. 1, 2005.
James W. Conine, Special Tablets, in Pharmaceutical Dosage Forms: Tablets vol. 1, 329 (Herbert A. Lieberman et al. eds, 1989).
Jan. 12, 2009 Ceph et al. v. Watson et al., Defendant's Objections and Responses to Plaintiff's First Set of Interrogatories, (No. 1-11), Case No. 08-330-SLR.
Jan. 13, 2011 Redacted Booker Declaration in Support of Plaintiffs Motion to Strike.
Jan. 13, 2011 Redacted Defendants Brief in Answering Brief in Opposition to Motion to Strike.
Jan. 13, 2011 Redacted Plaintiffs Brief in Support of Motion to Strike Defendants Not of Subsequent Authority.
Jan. 14, 2011 Ceph et al. v. Sandoz, Fourth Stipulated Amendment to Scheduling Order, Civil Action No. 10-123-SLR.
Jan. 18, 2011 Declaration of Gwinn in Support of Watson's Opposition to Ceph et al. Motion to Strike Watson's Notice of Subsequent Authority Pursuant to Local Rule 7.1.2(b), or in the Alternative, to Reopen the Record.
Jan. 18, 2011 Redacted Suzuki Declaration in Support of Def Answering Brief re Motion to Strike.
Jan. 18, 2011 Watson's Answering Brief in Opposition to Ceph et al. Motion to Strike Watsons' Notice of Subsequent Authority Pursuant to Local Rule 74.1.2(b), or in the Alternative to Reopen the Record.
Jan. 19, 2011 Cephalon Notice of Service re Supplemental Responses-Objections to Sandoz Notice of Deposition, Civil Action No. 10-123-SLR.
Jan. 19, 2011 Redacted Suzuki Declaration in Support of Motion to Vacate with Exhibits 1-3.
Jan. 19, 2011 Text Order Granting 4th Stipulated Amendment to Scheduling Order, Civil Action No. 10-123-SLR.
Jan. 26, 2009 Ceph et al. v. Watson et al., Plaintiffs Responses to Defendants First Set of Interrogatories, (Nos. 1-10) Civil Action No. 08-455-SLR.
Jan. 27, 2009 Ceph et al. v. Barr et al., Answer, Affirmative Defenses and Counterclaims, Case No. 08-cv-810 SLR.
Jan. 28, 2011 Redacted Bradway Declaration in Support of Plaintiffs Opposition to Defendants Motion to Vacate.
Jan. 28, 2011 Redacted Campbell Declaration in Support of Plntffs to Dfndnts Motion to Vacate.
Jan. 28, 2011 Redacted Plaintiffs Opposition to Defendants Motion to Vacate.
Jan. 28, 2011 Redacted Plaintiffs reply in Support of Motion to Strike with Exhibits 1-3.
Jan. 30, 2009 Ceph et al. v. Barr et al., Complaint for Patent Infringement Case No. 1:09-cv-00074-UNA.
Jan. 31, 2011 Ceph v. Sandoz, Order Setting Teleconference to Discuss Feb. 7, 2011 Mediation.
Jan. 6, 2011 Ceph et al. v. Sandoz, Proposed Stipulated Protective Order, Civil Action No. 10-123-SLR.
Jan. 7, 2011 Ceph et al. v. Sandoz, Signed Protective Order via email.
Jan. 9, 2009, Ceph et al. v. Barr Pharma et al., Barr's Responses and Objection to Ceph et al., First Set of Interrogatories (No. 1-10).
Jul. 15, 2008 Sealed Opening Brief in Support re 12 Motion to Dismiss for Failure to State a Claim, (Watson Pharmaceuticals, Inc's Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(6) and (7)) . . . .
Jul. 15, 2008 Sealed Opening Brief in Support re 15 Motion to Dismiss for Lack of Jurisdiction Over the Person, Motion to Dismiss for Failure to State a Claim by Watson Laboratories Inc., Answering Brief/Response due date per Local Rules is Aug. 1, 2008 (Fineman, Steven)(Entered Jul. 15, 2008), (Watson Labs, Inc's Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(6) and (7).
Jul. 15, 2008 Watson Labs Motion to Dismiss for Failure to Join a Party, Pursuant to Fed. R. Civ. P. 12(b)(6) and (7), Case No. 08-330-JJF.
Jul. 15, 2008 Watson Pharmaceuticals Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(6) and (7).
Jul. 20, 2010 Order Scheduling ADR Teleconference, C.A. No. 10-123-SLR-LPS. Ceph et al. v. Sandoz.
Jul. 22, 2008 Ceph et al. v. Barr et al., Complaint for Patent Infringement.
Jul. 22, 2008 Redacted version of 14 Opening Brief in Support of Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(6) and (7) by Watson Pharmaceuticals, Inc. Watson Laboratories Inc. (Attchmnent #1, Ex. #2, Ex. 2, #3, Ex 3) Stephen Fineman. Case No. 08-330-JJF.
Jul. 22, 2008 Redacted version of 17 Opening Brief in Support of Motion to Dismiss, Pursuant to Fed. R. Civ. P. 12(b)(2) and (6) by Watson Pharmaceuticals Inc., Watson Laboratories Inc., (Attchmnts—Ex. 1, #2, Ex. 2, #3, Ex 3) Stephen Fineman Case No. 08-330-JJF.
Jul. 22, 2008 Redacted Watson Pharma Opening Brief in Support of Motion to Dismiss, Case No. 08-330-JJF.
Jul. 29, 2010 Stipulated Amendment to Scheduling Order re: Doc Production, C.A. No. 10-123-SLR. Ceph et al. v. Sandoz.
Jul. 30, 2010 Plaintiffs Responsive Post-Trial Brief on Validity.
Jul. 30, 2010 Redacted Defendants Responsive Post-Trial Brief.
Jul. 30, 2010 Redacted Watson Motion to Strike Expert Testimony.
Jun. 2, 2008 Report of Filing an Action, Docket No. 08-cv-330.
Jun. 29, 2010 Redacted plaintiffs Opening Post-Trial Brief.
Jun. 29, 2010 Redacted Watson Opening Post-Trial Brief.
Jun. 3, 2010 Order Regarding Discovery Matters, C.A. No. 10-123-SLR-LPS.
Jun. 3, 2010 Scheduling Order Entered via email, Ceph et al. v. Sandoz.
Kellaway, I.W., and Warren, S.J., "Mucoadhesive Hydrogels for Buccal Delivery" Oral Mucosal Drug Delivery, Ch. 10, pp. 221-237 (1996).
Kramer TH, d'Amours RH, Buettner C. Pharmacodynamic model of the effects of morphine and morphine-6-glucuronide during patient controlled analgesia [abstract]. Clin Pharmacol Ther 1996; 59: 132.
Labroo RB, Paine ME, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy and drug interactions. Drug Metab Dispos 1997; 25 (9): 1072-80.
Malpani, "Sodium Starch Glycolate", 13 pages, Jan. 5, 2010.
Mar. 10, 2010 Stipulation and Order to Extend Time re: Answer to Complaint, Ceph et al. v. Sandoz.
Mar. 10, 2011 Redacted 79 Ltr to Thynge (Fish & Richardson) Marsden re Motion to Compel Discovery by Cephalon et al.—Attchmnt 1-6.
Mar. 10, 2011 Redacted Sealed Letter to Thynge (Fish & Richardson) Shaw re Plaintiff's Mar. 11, 2011 letter to the Court.
Mar. 10, 2011 Redacted Version 82 Letter, to The Honorable Mary Pat Thynge from John W. Shaw on behalf of Defendant Sandoz Inc. regarding response to Plaintiffs' Mar. 3, 2011 letter to the Court by Sandoz Inc. (Attachments: # 1 Exhibit A-D)(Keller, Karen) (Entered: Mar. 17, 2011).
Mar. 11, 2010 Text Order Granting Stipulation to Extend Time to Answer, Ceph et al. v. Sandoz.
Mar. 11, 2011 Opinion, Ceph v. Watson, C.A. No. 08-330-SLR (D. Del. Mar. 11, 2011) (Robinson, J.).
Mar. 11, 2011 Order, Ceph v. Watson, C.A. No. 08-330-SLR, (D. Del. Mar. 11, 2011).
Mar. 11, 2011 Order—Teleconference Transcript Stands as Order of Court re Navinta Discover, C.A. No. 10-123-SLR/MPT.
Mar. 13, 2009 Ceph et al. v. Barr et al., Answer to Counterclaims, Civil Action No. 09-074 SLR.
Mar. 15, 2010 Redacted Watson Answering Brief in Opposition of Motion to Modify Protective Orders.
Mar. 18, 2011 Ceph et al. v. Mylan et al., Stipulation to Extend Time to Answer Complaint, Civ. No. 11-164-SLR.
Mar. 2, 2011 Executed Summons re Mylan Pharma., served Feb. 25, 2012.
Mar. 22, 2010 Sandoz Answer, Defense, Counterclaims, C.A. No. 10-00123-SLR.
Mar. 22, 2010 Sandoz Inc's Rule 7.1 Disclosure Statement, C.A. No. 10-00123-SLR.
Mar. 22, 2010 Sandoz Pro Hac Vice Motion and Order—Gargano of McDermott.
Mar. 22, 2011 email re; Order Granting Stipulation to Extend Time.
Mar. 23, 2009 Redacted Version of 117 Answering Brief in Opposition to Watson et al., Motion to Dismiss, C.A. No. 08-330-SLR.
Mar. 23, 2009 Redacted Version of 117 Oakes Declaration in Support of Opposition to Watson Pharma., Motion to Dismiss Amended Complaint, C.A. No. 08-330-SLR.
Mar. 23, 2010 Sandoz Pro Hac Vice Motion—Garcha-Dolkas-Chang-Boyle of McDermott, C.A. No. 10-00123-SLR.
Mar. 24, 2010 So Ordered—re 10 Motion for Pro Hac Vice Appearance of Attorney Jeffrey R. Gargano. Signed by Judge Sue L. Robinson on Mar. 24, 2010. (lid) (Entered: Mar. 24, 2010).
Mar. 25, 2011 Mylan Answer to Complaint w/ Counterclaim.
Mar. 25, 2011 Mylan Disclosure Statement, C.A. No. 1:11-cv-0164-SLR.
Mar. 25, 2011 Mylan Pharmaceuticals Disclosure Statement, Civil Action No. 1:11-cv-0164 SLR.
Mar. 25, 2011 Order Setting Discovery Teleconference w/Thynge, C.A. No. 10-123-SLR-MPT.
Mar. 25, 2011 Plaintiff Notice of Service of Williams Rebuttal Expert Report, C.A. No. 10-123-SLR.
Mar. 25, 2011 Substitution of Counsel, Civ. No. 1:11-cv-0164.
Mar. 28, 2011 Fish & Richardson Letter to Thynge enclosing courtesy Motion to Stay.
Mar. 28, 2011 Plaintiffs Motion to Stay, Proposed Order, C.A. No. 10-123-SLR/MPT.
Mar. 28, 2011 Sealed Opening Brief in Support re 88 Plaintiff's Motion to Stay, C.A. No. 10-123-SLR/MPT, 18 pp.
Mar. 29, 2011 Ceph et al. v. Mylan et al., Document 14 (dated Mar. 29, 2010)Pro Hac Motion and Order for Admission(s) re Figg and Bhatt of Rothwell Figg to represent defendants, Mylan et al., C.A. No. 11-0164-SLR.
Mar. 29, 2011 Fish & Richardson Letter to Thynge, Ceph et al. v. Sandoz re: teleconference for Plaintiff's Motion to Stay Action and Opening Brief.
Mar. 29, 2011 Fish & Richardson Redacted Letter to Thynge (McCann) re Discovery Extension—Proposed Order C.A. No. 10-123-SLR/MPT.
Mar. 29, 2011 Letter to Thynge (Fish and Richardson) McCann enclosed courtesy Motion to Stay, Civil Action No. 10-123-SLR-MPT.
Mar. 29, 2011 Poff ltr to Thynge re Defendant, Sandoz Response to Plaintiff's Mr. 28, 2011 Ltr.
Mar. 29, 2011 Redacted Letter to Thynge (Fish and Richardson) McCann re: Courtesy Plaintiff's Motion to Stay Action and Opening Brief in anticipation of teleconference.
Mar. 29, 2011 Sandoz Notice of Service of Polli Suppl. and Rebuttal Expert Reports, C.A. No. 10-123-SLR.
Mar. 3, 2011 Sealed Letter to Thynge (Fish & Richardson) Marsden re: pending Motion to Compel Discovery.
Mar. 30, 2009 Ceph et al. v Watson, Defendant's Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories, C.A. No. 08-330-SLR.
Mar. 30, 2009 Ceph et al. v. Barr et al., Plaintiff's Supplemental Response to Defendants' First Set of Interrogatories (Nos. 1-10).
Mar. 30, 2010 Ceph et al. v. Watson et al., Defendant's Answering Claim Construction Brief.
Mar. 30, 2010 Redacted Cephalon Marksman Brief.
Mar. 30, 2010 Redacted Watson Pharma Rebuttal Marksman Brief.
Mar. 31, 2010 Text Order re: Pro Hac Admission of McDermott Attorneys for Sandoz vial email.
Mar. 5, 2010 Ceph. v. Watson, Watson Opening Claim Construction Brief.
Mar. 5, 2010 Redacted Fineman Declaration in Support of Watson Opening Claim Brief.
Mar. 5, 2010 Redacted Plaintiffs Consolidated Opening Marksman Brief.
Mar. 6, 2009 Redacted Version of 96 Opening Brief in Support of Its Motion to Dismiss Counts 1, 2, 4, and 5 of the Amended Complaint pursuant to Fed. R Civ. P. 12(b)(6) and (7) and Defendants' Opening Brief in Support Their Motion to Dismiss Counts 3 and 6 of the Amended Complaint pursuant to Fed. R. Civ. P. 12(B)(1) by Watson Pharm, Inc., Watson Pharmaceuticals Inc, Watson Laboratories, (Fineman, Steven).
Mar. 6, 2009 Redacted Version of 97 Declaration of H. Sarah Park dated Feb. 20, 2009 in Support of Watson Defendant's Motion to Dismiss by Watson Pharma, Inc., Watson Pharmaceuticals, Watson Laboratories Inc., (Attachments #1 Exhibits 1-30) Fineman, Steven.
Mar. 8, 2011 Order Setting Teleconference re Discovery Issue, C.A. No. 10-123-SLR/MPT.
May 11, 2010 Order Regarding Teleconference—Court Docket Error, to Watson and Barr from Doug McCann.
May 11, 2010 Proposed Scheduling Order, C.A. No. 10-123-SLR. Ceph et al. v. Sandoz.
May 18, 2009 Ceph et al. v. Watson et al., Answer to Counterclaims by Cephalon Inc., CIMA Labs Inc., (McCann Douglas).
May 18, 2012 Appellee's Brief, Ceph. et al. v. Watson, 68 pages.
May 2, 2011 Redacted Version of 105 Plaintiff's Reply Brief in Support of Plaintiff's Motion to Stay Proceedings (Attachments #1 Ex. A).
May 2, 2011 Redacted Version of 107 Claim Construction Opening Brief Plaintiff's Opening Claim Construction Brief.
May 2, 2011 Redacted Version of 108 Declaration of Oakes in Support of Plaintiffs Opening Claim Construction Brief by Plaintiffs.
May 20, 2010 Final Proposed Scheduling Order, C.A. No. 10-123-SLR, Ceph et al. v. Sandoz.
May 24, 2010 Order re: Teleconference vial email, Ceph et al. v. Sandoz.
May 24, 2010 Order re: Teleconference—via email, Ceph et al. v. Mylan et al.
May 25, 2010 Notice of Service re Plaintiffs Initial Disclosures, Civil Action No. 10-330-SLR. Ceph et al. v. Sandoz.
May 25, 2010 Notice of Service re: Defendants Initial Disclosures, Civil Action No. 10-123-SLR. Ceph et al. v. Sandoz.
May 29, 2009 Ceph et al. v. Barr et al., Plaintiffs' Second Set of Interrogatories (Nos. 1-10) Civil Action No. 08-455-SLR.
May 29, 2009 Ceph et al. v. Barr et al., Plaintiffs' Second Supplemental Response to Defendants' First Set of Interrogatories (Nos. 1-10).
May 9, 2011 Notice of Docketing, United States Court of Appeals for the Federal Circuit, Case: 1:08-cv-00330-SLR, Document 340.
Mechanistic Studies on Effervescent-Induced Permeability Enhancement by Jonathan D. Eichman, a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmacy) at the University of Wisconsin-Madison 1997.
Mylan et al. Notice of Paragraph IV Certification: Amendment to ANDA No. 202577 Fentanyl Citrate Buccal Tablets, (Flynn), dated Sep. 28, 2011.
Nishimura et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa VI: Formulation of Effervescent Enteric-Coated Tablets" J. Pharm. Sci. 73(7):942-46 (1984).
Notice of Reference cited from the Examiner re: U.S. Appl. No. 12/955,346.
Nov. 1, 2010 Cephalon Notice of Service re: Responses and Objections to Sandoz Notice of Deposition, Civil Action No. 10-123-SLR.
Nov. 12, 2010 Ceph et al. v. Sandoz, Cephalon Notice of Service re: Supplemental Responses to 1st Set of Interrogatories—Nos. 3 and 5, Civil Action No. 10-123-SLR.
Nov. 16, 2011 Appellee's Brief, Ceph. et al. v. Watson, 148 pages.
Nov. 18, 2010 Ceph et al. v. Sandoz, Sandoz Notice of Service Objections to Cephalon Subpoena to Navinta, Civil Action No. 10-123-SLR.
Nov. 18, 2010 Ceph et al. v. Sandoz, Sandoz Notice of Subpoenas to Anesta-Coleman-Zhang, Civil Action No. 10-123-SLR.
Nov. 24, 2010 Ceph et al. v. Sandoz, Notice of Service of Responses and Objections of Non-Party Anesta to Sandoz, Inc.'s Subpoena Duces Tecum by Anesta Corp. (McCann).
Nov. 24, 2010 Notice of Service of Responses and Objections of Non-Party Dennis Coleman to Sandoz, Inc.'s Subpoena Ad Testificandum and Duces Tecum by Dennis Coleman, Civil Action No. 10-123-SLR.
Nov. 3, 2008, Ceph et al. v. Watson et al., Answer to Counterclaims, Case No. 3:08-cv-00308-LHR-RAM.
Nov. 5, 2010 Plaintiffs Notice of Service, Civil Action No. 10-123-SLR.
Oct. 1, 2010 Stipulated Amendment to SO re: Doc Production and Claim Terms Exchange, Civil Action No. 10-123-SLR. Ceph et al. v. Sandoz.
Oct. 12, 2010 Cephalon Notice of Service re: Responses and Objections to Sandoz 1st Interrogatories and Request for Production of Documents, Civil Action No. 10-123-SLR.
Oct. 12, 2010 Sandoz Notice of Service re: Responses and Objections to Cephalon 1st Interrogatories and Request for Production of Documents, Civil Action No. 10-123-SLR.
Oct. 14, 2008 Ceph et al. v. Watson et al., Answer and Counterclaims, Case No. 3:08-CV-308-LRH-RAM.
Oct. 18, 2010 Cephalon Notice of Deposition to Sandoz, Civil Action No. 10-123-SLR.
Oct. 18, 2010 Sandoz Notice of Service, Civil Action No. 10-123-SLR.
Oct. 25, 2010 Cephalon Notice of Deposition of Allison Sherwood, Civil Action No. 10-123-SLR.
Oct. 25, 2010 Cephalon Notice of Deposition of Ellen Camos, Civil Action No. 10-123-SLR.
Oct. 25, 2010 Cephalon Notice of Deposition of Indranil Nandi, Civil Action No. 10-123-SLR.
Oct. 25, 2010 Order Setting Mediation Conference, C.A. No. 10-123-SLR/MPT, Ceph et al. v. Sandoz.
Oct. 26, 2010 Cephalon Subpoena Executed re: Navinta Civil Action No. 10-123-SLR.
Oct. 26, 2010 Notice of Subpoena, the attached subpoena's directed to Cohen, Millett and Lerner David on Oct. 25, 2010. Ceph et al. v. Sandoz.
Oct. 26, 2010 Sandoz Notice of Subpoenas Duces Tecum and Ad Testificadum on Navinta LLC by CIMA/Cephalon (Compton) Civil Action No. 10-123-SLR.
Oct. 26, 2010 Sandoz Notice of Subpoenas to Lerner David, Civil Action No. 10-123-SLR.
Oct. 27, 2010 Sandoz Notice of Subpoenas to Univ of WI-Madison, Civ Action No. 10-123-SLR.
Oct. 29, 2008 Ceph et al. v. Barr et al., Complaint for Patent Infringement.
Oct. 29, 2010 Sandoz Notice of Service re: 2nd Notice of Deposition of CIMA and Ceph., Civil Action No. 10-123-SLR.
Oct. 29, 2010 Sandoz Notice of Subpoena to Jason Garbell, Civil Action No. 10-123-SLR.
Oct. 5, 2010 Text Order Granting Stipulated Amendment to Scheduling Order via Email.
Palmisano, Clinical Review of Fentanyl Oralet (Oral Transmucosal Fentanyl Citrate), NDA Application No. 20-195/S-002, dated Feb. 26, 1996.
Pather et al.,"Buccal Delivery-Enhanced Buccal Delivery of Fentanyl Using the Oravescent Drug Delivery System", Drug Delivery Tech. , vol. 1, No. 1, Oct. 2001.
Pather et al.,"Buccal Delivery—Enhanced Buccal Delivery of Fentanyl Using the Oravescent Drug Delivery System", Drug Delivery Tech. , vol. 1, No. 1, Oct. 2001.
Pather SI, Siebert JM, Hontz J, et al. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system [online]. Drug Delivery Tech Oct. 2001; 1 (1): 54-7. Available at URL: http://drugdeliverytech.com/cgi-bin/issues.cgi?idIssue = 1 [Accessed Jun. 23, 2001].
Pharmaceutical Dosage Forms-Tablets vol. 1, 2nd ed., Herbert A. Lieberman, ed. pp. 372-376.
Pharmaceutical Dosage Forms—Tablets vol. 1, 2nd ed., Herbert A. Lieberman, ed. pp. 372-376.
Portenoy et al., "Fentanyl Buccal Tablet (FBT) for Relief of Breakthrough Pain in Opioid-Treated Patients with Chronic Low Back Pain: A Randomized, Placebo-Controlled Study", Fentanyl Buccal Tablet for Breakthrough Pain, vol. 23(1), pp. 223-233, (2007).
Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41 (3): 273-81.
Prescribing information: ACTIQ® (oral transmucosal fentanyl citrate). Physicians' Desk Reference®. 58th ed. Montvale, NJ: Medical Economics Company, Inc.; 2004: 1151-5.
Prescribing information: KADIAN® (morphine sulfate sustained release capsules) Physicians' Desk Reference®. 59th ed. Montvale, NJ: Medical Economics Company, Inc.; 2005: 569-73.
Ranade, V.V.; Drug Delivery Systems Part 5B. Oral Drug Delivery, The Journal of Clinical Pharmacology, Feb. 1991, pp. 98-115, vol. 31.
Rassing, M.R., "Specialized Oral Mucosal Drug Delivery Systems: Chewing Gum" Oral Mucosal Drug Delivery, Ch. 13, pp. 319-353 (1996).
Rassing, R., "Specialized Oral Mucosal Drug Delivery Systems: Chewing Gum" Oral Mucosal Drug Delivery, Ch. 13, pp. 319-353 (1996).
Rathbone et al., "In Vivo Techniques for Studying the Oral Mucosal Absorption Characteristics of Drugs in Animals and Humans" Oral Mucosal Drug Delivery, Ch. 7, pp. 121-151 (1996).
Rathbone et al., "Systemic Oral Mucosal Drug Delivery and Delivery Systems" Oral Mucosal Drug Delivery, Ch. 11, pp. 241-275 (1996).
Resine T, Pasternak G. Opioid analgesics and antagonists. In Hardman JG, Limbird LE, Molinoff PB, et al, editors. Goodman and Gilman's pharmacologic basis of therapeutics. 9th rev. ed. New York: McGraw-Hill, 1996: 521-55.
Rowe et al., Handbook of Pharamceutical Excipients, 2006, Fifth Edition, pp. 758-759.
Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients", J. Pharm. Sci. vol. 69(3), pp. 261-265, (1980).
Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa III: Influence of Dose on Pharmacokinetic Behavior of Levodopa in Dogs and Parkinsonian Patients" J. Pharm. Sci. 69(12):1374-78 (1980).
Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa V: Absorption and Metabolism of Levodopa in Intestinal Segments of Dogs" J. Pharm. Sci. 70(10):1157-60 (1981).
Sasahara et al., "Dosage Form Design for Improvement of Bioavailibity of Levodopa IV: Possible Causes of Low Bioavailability of Oral Levodopa in Dogs" J. Pharm. Sci. 70(7):730-33 (1981).
Schenkels et al., "Salivary Mucins: Their Role in Oral Mucosal Barrier Function and Drug Delivery" Oral Mucosal Drug Delivery, Ch. 9, pp. 191-211 (1996).
Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985; 62 (3): 234-41.
Sep. 1, 2010 Cephalon Notice of Entry of Appearance of Compton (FR), Civil Action No. 10-123-SLR. Ceph et al. v. Sandoz.
Sep. 10, 2010 Redacted Corrected Watson Reply Post Trial Brief.
Sep. 17, 2008 Stern Kessler Letter.
Sep. 18, 2008, Ceph et al., v. Watson et al., Defendants First Set of Rule 33 Interrogatories to Plntiffs, Case No. 08-330-JJF.
Sep. 22, 2010 Order Setting Teleconference with MJ Thynge, C.A. No. 10-123-SLR.
Sep. 4, 2008 Ceph et al. v. Barr et al., Answer to Counterclaims.
Sorasuchart, W.; Wardrop, J.; Ayers, J.; Drug Release from Spray Layered and Coated Drug-Containing Beads: Effects of pH and Comparison of Different Dissolution Methods, Drug Development and Industrial Pharmacy, 1999, pp. 1093-1098, vol. 25, No. 10.
Soskolone, W.A., and Friedman, M., "Intra-periodontal Pocket Drug Delivery Systems" Oral Mucosal Drug Delivery, Ch. 14, pp. 359-373 (1996).
Squier, C.A., and Wertz, P.W., "Structure and Function of the Oral Mucosa and Implications for Drug Delivery" Oral Mucosal Drug Delivery, Ch. 1, pp. 1-19 (1996).
Stanley et al, "Novel Delivery Systems: Oral Transmucosal and Intranasal Transmucosal", Journal of Pain and Sympton Management, vol. 7, No. 3, Apr. 1992, pp. 163-171.
Sterne Kessler et al., Ltr re: Barr Supplemental Notification Pursuant to §505(j)(2)(B)(ii) of the Federal Food Drug, and Cosmetic Act, 7 pages, Dated Dec. 22, 2008.
Sterne, Kessler, Letter dated Jun. 27, 2008.
Sterne, Kessler, Letter dated Jun. 9, 2008.
Streisand et al., "Buccal absorption of fentanyl is pH-dependent in dogs", Anesthesiology, (Mar. 1995), 82 (3), pp. 759-764.
Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75 (2): 223-9.
Streubel, A.; Siepmann, J.; Dashevsky, A.; Bodmeier, R.; pH-Independent Release of a Weakly Basic Drug from Water-Insoluble and -Soluble Matrix Tablets, Journal of Controlled Release, 2000, pp. 101-110, vol. 67.
Stumm W, Morgan JJ. Aquatic chemistry. New York: Wiley-Interscience, 1970.
Susanne Bredenberg, "New Concepts in Administration of Drugs in Tablet Form" Thesis (comprehensive summaries of Uppsala Dissertations from the Faculty of Pharmacy 287) 2003.
The Alcohol and Other Drug Thesaurus, National Institute of Health, National Institute on Alcohol Abuse and Alcoholism (Third Edition, 2000, U.S. Dept. of Health and Human Services).
U.S. Appl. No. 09/661,693, filed Sep. 14, 2000.
U.S. Appl. No. 10/936,185, Pather et al.
Wada, et al., Decision on Appeal 2007-3733, re: U.S. Appl. No. 10/613,220, pp. 1-9, Decided Jan. 14, 2008.
Weatherell et al., "The Flow of Saliva and its Influence on the Movement, Deposition, and Removal of Drugs Administered to the Oral Cavity" Oral Mucosal Drug Delivery, Ch. 8, pp. 157-187 (1996).
Weinberg et al., "Sublingual absorption of selected opioid analgesics", Clinical Pharmacology and Therapeutics, Sep. 1988, 44 (3), pp. 335-342.
Wertz et al., "Biochemical Basis of the Permeability Barrier in Skin and Oral Mucosa" Oral Mucosal Drug Delivery, Ch. 2, pp. 27-41 (1996).
Zhang, H., and Robinson, J.R., "In Vitro Methods for Measuring Permeability of the Oral Mucosa" Oral Mucosal Drug Delivery, Ch. 5, pp. 85-97 (1996).
Zhang, H., and Robinson, J.R., "Routes of Drug Transport Across Oral Mucosa" Oral Mucosal Drug Delivery, Ch. 3, pp. 51-61 (1996).
US20060292219A1 (en) 2006-12-28 application
US20050064030A1 (en) 2005-03-24 application
US20030091629A1 (en) 2003-05-15 application
US5614207A (en) 1997-03-25 Dry mouth lozenge
US6649186B1 (en) 2003-11-18 Effervescent granules and methods for their preparation
US6391886B1 (en) 2002-05-21 Oral compositions having improved consumer aesthetics
US6488961B1 (en) 2002-12-03 Effervescent granules and methods for their preparation
US6316027B1 (en) 2001-11-13 Fast-dissolving dosage forms for dopamine agonists
US6576250B1 (en) 2003-06-10 Pharmaceutical compositions for rectal and vaginal administration
US20050038039A1 (en) 2005-02-17 Formulations
US20050065175A1 (en) 2005-03-24 Oral transmucosal methadone
US20060073189A1 (en) 2006-04-06 Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
US6183775B1 (en) 2001-02-06 Buccal delivery system
US20040138098A1 (en) 2004-07-15 Pharmaceutical compositions including low dosages of desmopressin
US20030185884A1 (en) 2003-10-02 Therapeutic agent delivery compositions for buccal cavity absorption of pilocarpine
US6680071B1 (en) 2004-01-20 Opioid agonist in a fast dispersing dosage form
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CIMA LABS INC.;REEL/FRAME:026446/0063